SG001

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SG001 is one of 135 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

Cervical CancerActive, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Cervical CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

94 2

Erbitux

Lenvima

1 4

Azulfidine

Pfizer

Phase 3

1 5

Celebrex

PPhiladelphia Eye Associates

Phase 3

9 6

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Phase 3

1 7

PF-08634404

Pfizer

Phase 3

—8

SG001

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

1 9

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

1 10

Napabucasin

Sumitomo Pharma America, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Advanced Solid Tumors

NCT06132217

Q4 2027

Phase 1/2Not yet recruiting

Locally Advanced or Metastatic Solid Tumors

NCT06682611

Q2 2028

Phase 1/2Not yet recruiting

Locally Advanced Unresectable Esophageal Squamous Carcinoma

NCT06136988

Q3 2028

Phase 2Not yet recruiting

HNSCC

NCT06989671

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06132217·168 enrolled

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT05508659·128 enrolled

Cervical Cancer2 trials

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT04886700·104 enrolled

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05715840·368 enrolled

Metastatic Colorectal Cancer1 trial

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT06089330·102 enrolled

HNSCC1 trial

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT06989671·430 enrolled

Biliary Tract Cancer1 trial

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Terminated·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT05009953·17 enrolled

6 more indications

Locally Advanced or Metastatic Solid Tumors1 trial

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT04983550·126 enrolled

Monoclonal1 trial

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT03852823·192 enrolled

Hypofractionated Radiotherapy1 trial

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Recruiting·FFudan University·Phase 2·NCT07183865·44 enrolled

Triple-Negative Breast Cancer1 trial

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05068141·79 enrolled

Locally Advanced Unresectable Esophageal Squamous Carcinoma1 trial

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT06136988·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for SG001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SG001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SG001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SG001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Advanced Solid Tumors2 trials

Cervical Cancer2 trials

Metastatic Colorectal Cancer1 trial

HNSCC1 trial

Biliary Tract Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Efficacy and Safety1 trial

Monoclonal1 trial

Hypofractionated Radiotherapy1 trial

Triple-Negative Breast Cancer1 trial

Locally Advanced Unresectable Esophageal Squamous Carcinoma1 trial

References

Drug Info

Quick Facts

Related News